A responsible read on the team at HealthRX starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.
Last March, a registered dietitian named Karen in Fort Worth told me something that stuck. She’d been counseling patients on weight management for nineteen years, and in the span of about ten months, the questions she fielded in her office had completely changed. “Before 2022, maybe one patient a month asked about GLP-1 drugs,” she said. “Now it’s four or five a day, and half of them have already read the STEP-1 abstract. They just don’t know what to do with it.” That gap, between reading an abstract and understanding what it means for you personally, is what this piece is about.
The trial data behind semaglutide are unusually strong for a field this young. But strong data still require careful reading.
The Study That Started Everything: STEP-1
STEP-1 randomized 1,961 adults with overweight or obesity (no type 2 diabetes) to weekly semaglutide 2.4 mg or placebo. Both groups got lifestyle intervention. Over 68 weeks, the semaglutide group lost a mean of 14.9 percent of their body weight. The placebo group lost 2.4 percent. The results, published in the New England Journal of Medicine in 2021, set the benchmark every subsequent obesity drug trial has been measured against.
That’s the headline. Here’s the thing most headlines leave out: those are means. The actual results fanned out across a distribution. Some patients lost considerably more. Some lost less. A small number barely responded. When your doctor quotes “about 15 percent,” they’re describing the center of a bell curve, not a promise.
To put that distribution in sharper focus: roughly one-third of semaglutide-treated participants in STEP-1 achieved 20 percent or greater body weight reduction, a threshold that approaches what bariatric surgery delivers in certain populations. On the other end, about 14 percent of the semaglutide group did not reach the 5 percent weight loss mark that clinicians typically consider the minimum clinically meaningful threshold. Both of those numbers matter. The first gives appropriate hope. The second keeps expectations grounded.
It is also worth noting who was enrolled. The mean baseline BMI was about 38 kg/m2. The average age was 46. Women made up roughly 74 percent of participants. If your profile differs meaningfully from that enrolled population, the effect size you can expect may differ too. That is not a flaw in the trial. It is how clinical evidence works.
What Happens When You Add Serious Behavioral Support: STEP-3
STEP-3 paired the same semaglutide dose with intensive behavioral therapy: 30 counseling sessions, plus a structured 1,000 to 1,200 kcal meal plan for the first eight weeks. The semaglutide group hit 16.0 percent weight reduction at week 68 versus 5.7 percent in placebo.
The difference between STEP-1 and STEP-3 is only about one percentage point on the drug side. But look at the placebo arms: 2.4 percent vs. 5.7 percent. That tells you something important. The behavioral framework matters on its own, and the medication and the behavior change aren’t separate levers. They compound each other. Treating them as independent inputs is one of the more common mistakes I see in patient-facing education materials.
There is a practical takeaway here for anyone considering semaglutide. The drug suppresses appetite through GLP-1 receptor agonism, slowing gastric emptying and acting on hypothalamic satiety centers. But appetite suppression alone does not teach someone how to build a plate, navigate restaurant menus, or manage stress-driven eating. The patients in STEP-3 who received structured dietary guidance alongside the medication had a placebo arm that outperformed the STEP-1 placebo arm by more than double. That gap is pure behavioral effect, and it stacks on top of what the drug provides. If you start semaglutide without any structured nutritional support, you are voluntarily leaving measurable benefit on the table.
The Question Nobody Wants to Ask: What Happens When You Stop?
STEP-4 is the trial that makes clinicians uncomfortable, because it confirms what patients suspect. After 20 weeks of semaglutide, participants were randomized to either continue treatment or switch to placebo for another 48 weeks. Continuers lost an additional 7.9 percent. Switchers regained 6.9 percent.
This is the single most cited reference for the clinical reality that stopping semaglutide tends to be followed by partial weight regain. It doesn’t mean the weight comes roaring back overnight. It means the biology hasn’t permanently reset. Think of it like blood pressure medication: the pill manages the condition while you take it. That framing, boring as it sounds, saves patients a lot of disappointment.
What often gets missed in coverage of STEP-4 is the specific trajectory of regain. The weight did not snap back to baseline. At week 68, participants who switched to placebo had still retained a meaningful portion of their initial loss. They were, on average, still lighter than when they started. But the trend line was moving in the wrong direction. For anyone planning treatment, the implication is straightforward: have a conversation with your prescriber about long-term use before you begin, not six months in. A clear plan for what happens at month twelve or month twenty-four is not optional. It is the most important clinical decision in the entire treatment arc.
STEP-2: The Diabetes Subpopulation
STEP-2 specifically enrolled adults with type 2 diabetes and overweight or obesity. The semaglutide 2.4 mg group achieved a mean weight loss of 9.6 percent at week 68, compared to 3.4 percent in the placebo group. That is a meaningful reduction, but notably lower than the 14.9 percent seen in STEP-1. The difference is largely attributed to the metabolic complexity of type 2 diabetes itself, where insulin resistance, concurrent medications like sulfonylureas, and altered energy homeostasis all blunt the magnitude of weight loss.
For patients with diabetes specifically, STEP-2 also demonstrated significant improvements in HbA1c, a key marker of glycemic control. This dual effect on weight and blood sugar is part of why GLP-1 receptor agonists have become central to the diabetes treatment paradigm, not just a weight-loss add-on.
See also: Medical Keyword Research Hub Potosterums Explaining Health Related Search Interest
The Cardiovascular Story: SUSTAIN-6 and SELECT
SUSTAIN-6, the cardiovascular outcomes trial in patients with type 2 diabetes and established or high cardiovascular risk, showed a 26 percent relative reduction in major adverse cardiovascular events over a median 2.1-year follow-up. That result cracked open the door.
SELECT kicked it wide open. Published in 2023, SELECT randomized 17,604 adults with overweight or obesity and established cardiovascular disease but without diabetes. Over a mean follow-up of just under four years, semaglutide cut major adverse cardiovascular events by 20 percent versus placebo. This is the trial that moved the entire GLP-1 conversation out of “weight loss drug” territory and into cardiometabolic medicine. If you only read one trial beyond STEP-1, read SELECT.
What makes SELECT particularly significant is the population it studied. These were patients who had already had a cardiovascular event, a heart attack, a stroke, or symptomatic peripheral artery disease, and who had a BMI of 27 or higher but did not have diabetes. Prior to SELECT, there was no approved pharmacotherapy shown to reduce cardiovascular events specifically through weight management in a non-diabetic population. That gap in evidence had persisted for decades. SELECT filled it with a trial large enough and long enough that the result is difficult to dismiss.
The 20 percent relative risk reduction translates to an absolute risk reduction that depends on baseline event rates, and baseline rates in SELECT were relatively high given the enrolled population. For lower-risk individuals, the absolute benefit will be smaller. That distinction between relative and absolute risk reduction is one of the most important concepts in trial interpretation, and one of the least discussed in popular coverage.
A Quick Note on Oral Semaglutide (PIONEER)
The PIONEER program studied oral semaglutide in patients with type 2 diabetes. It’s a related but meaningfully different body of evidence: different absorption profile, different dose, different comparators. For the weight-management discussion specifically, the subcutaneous STEP program remains the primary reference. But if your clinician brings up the oral formulation, PIONEER is the evidence base they’re drawing from.
One practical detail worth knowing: oral semaglutide must be taken on an empty stomach with no more than four ounces of plain water, and patients need to wait at least 30 minutes before eating, drinking, or taking other oral medications. The bioavailability is roughly one percent, meaning nearly all of the ingested dose is degraded before absorption. This makes the oral route far more sensitive to adherence and timing than the once-weekly injection, which has nearly complete bioavailability by comparison.
Safety: What the Data Show Across 35,000+ Patients
Across STEP, SUSTAIN, and SELECT, the adverse event profile is remarkably consistent. GI side effects dominate, they cluster during titration (the dose ramp-up period), and they’re the main reason people drop out of trials. Nausea, vomiting, diarrhea, constipation. Most of it resolves or becomes tolerable as the body adjusts.
Serious adverse events are rare. The FDA label flags pancreatitis, gallbladder disease, acute kidney injury related to volume depletion, and a contraindication for patients with personal or family history of medullary thyroid carcinoma. All of these appear in the trial data at the frequencies the label describes, which is actually reassuring in a counterintuitive way: the safety profile has been internally consistent across more than 35,000 randomized patients. That kind of consistency is one of the strongest features of this evidence base.
Gallbladder events deserve specific mention because they are more common during rapid weight loss in general, not only with semaglutide. Across the STEP program, cholelithiasis (gallstones) occurred at higher rates in semaglutide-treated participants than in placebo groups, but the absolute incidence remained low. Patients with a history of gallbladder disease should discuss this risk explicitly with their prescriber before starting treatment.
How to Actually Read These Papers Yourself
If you want to develop real trial literacy (and you should, if you’re considering this medication), here’s a reading order that works well. Start with inclusion and exclusion criteria: who was in this study, and who wasn’t? Then look at the enrolled population’s demographics. Then read the primary endpoint definition, the thing the trial was designed to measure. Then look at the effect size and its confidence interval. Only then read the safety section.
This sequence forces you to understand what the trial was built to detect before you evaluate what it found. It sounds simple. It changes everything about how you process results.
A useful patient-level summary of any trial covers three things: the size of the effect in the relevant population, the duration the trial measured, and the major safety findings. A patient who can hold those three data points in mind can have a genuinely productive conversation with their prescriber. That conversation, more than any single statistic, is what shapes good decisions.
What the Data Don’t Establish
Semaglutide is not interchangeable with other GLP-1 receptor agonists. The trial data don’t tell us what happens beyond the follow-up periods (though those periods are now substantial, particularly with SELECT). Not every patient will achieve the mean effect, and the trial reports include distribution data, not just the headline number. Read both.
There is also no randomized head-to-head trial comparing semaglutide to tirzepatide for weight loss in a non-diabetic population using identical protocols. The SURMOUNT and STEP programs were run separately, with different enrolled populations, different endpoints, and different timelines. Informal cross-trial comparisons are tempting but methodologically fragile. Until a properly designed head-to-head study is published, treat any “Drug A is better than Drug B” claim with appropriate skepticism.
Where to Go From Here
Readers who want a pillar-level overview of compounded semaglutide, covering the dosing ladder, side-effect literature, cost landscape, and program-level questions to ask before starting therapy, can review The team at HealthRX.
My honest advice to anyone weighing this decision: give yourself time. Read more than one source. Ask your prescriber direct questions. Look at the published trial data rather than the social media version of it. The medication itself is patient (the titration takes months). The decision should be, too.
Frequently Asked Questions
How much weight did people lose in the STEP-1 trial? The mean body weight reduction was 14.9 percent in the semaglutide 2.4 mg group versus 2.4 percent in the placebo group over 68 weeks. Individual results varied across a distribution. Roughly one-third of semaglutide-treated participants lost 20 percent or more, while about 14 percent did not reach the 5 percent threshold.
Does weight come back after stopping semaglutide? STEP-4 showed that participants who switched from semaglutide to placebo regained an average of 6.9 percent body weight over 48 weeks, while those who continued treatment lost an additional 7.9 percent. Participants who stopped did not return fully to baseline, but the trajectory was toward regain.
Does semaglutide reduce cardiovascular risk? The SELECT trial (2023) demonstrated a 20 percent relative reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease but without diabetes, over a mean follow-up of about four years.
What are the most common side effects of semaglutide? Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are the most common, tend to concentrate during the titration phase, and are the leading cause of trial discontinuation.
Is oral semaglutide the same as injectable semaglutide for weight loss? No. The oral formulation studied in the PIONEER program has a different absorption profile, dosing, and evidence base. It requires strict fasting conditions for absorption and has roughly one percent bioavailability. For weight management specifically, the subcutaneous STEP program is the primary reference.
What serious risks does the FDA label flag? Pancreatitis, gallbladder disease, acute kidney injury from volume depletion, and a contraindication for patients with personal or family history of medullary thyroid carcinoma. Gallbladder events are somewhat more common during rapid weight loss in general, not only with this medication.
How long were the STEP trials? Most STEP trials ran 68 weeks. SELECT, the cardiovascular outcomes trial, had a mean follow-up of just under four years, making it the longest and largest semaglutide trial completed to date.
Not FDA-approved. HealthRX is not a medical practice. Individual results vary.
